Ventricular Tachycardia Antiarrhythmics or AblatioN In Structural Heart Disease 2 (VANISH2)

NCT02830360 Phase 4 COMPLETED

A multicenter, randomized clinical trial to assess whether catheter ablation or antiarrhythmic drug therapy provides the most effective control of important clinical outcomes for patients with prior myocardial infarction and sustained monomorphic ventricular tachycardia (VT).

Details

Lead sponsor	John Sapp
Phase	Phase 4
Status	COMPLETED
Enrolment	416
Start date	2016-10
Completion	2024-06-30

Conditions

• Ventricular Tachycardia (VT)

Interventions

• Antiarrythmic Drug Therapy
• Catheter ablation

Primary outcomes

• All-cause mortality — 8 years (including pilot study data)
  Time to any death occurring at any time post randomization
• Appropriate ICD shock at least 14 days post randomization — 8 years (including pilot study data)
  Time to first appropriate ICD shock after 14 days post randomization
• VT storm at least 14 days post randomization — 8 years (including pilot study data)
  Time to 3 or more episodes of VT within 24 hours
• Sustained VT requiring treatment at least 14 days post randomziation — 8 years (including pilot study data)
  Time to any sustained VT greater below the detection rate of the ICD requiring cardioversion (electrical or chemical) or manual ICD therapy at least 14 days post randomization

Countries

United States, Canada, France